New York's cigarette tax moved up to $2.75 per pack today, a move officials hope will drive as many as 140,000 smokers to quit. Jill Barshay gets some smokers' reactions.
The prognosis appears good for Massachusetts' health insurance mandate. A new report concludes the state is meeting its goal of reducing the number of uninsured citizens. Sarah Gardner reports.
A study out this morning spells out the cost of medical mistakes at children's hospitals. Nancy Marshall Genzer reports why doctors have a stronger incentive now to take care of preventable "adverse events."
A cancer drug used to treat colon, head and neck cancer is said to boost survival rates in patients with certain type of lung cancer. Janet Babin reports dramatic Erbitux trial results could make prescriptions explode.
The Howard Hughes Medical Institute is giving $600 million to a group of 56 scientists. Jeremy Hobson reports what this could mean for biomedical research in general, which often has to get creative to find funding.
When preparing for their big day, brides have another small detail to consider: How fit they'll look in that strapless gown. Many brides are flocking to the gym before they walk down the aisle. Jill Barshay reports.
To sniff out possible safety problems with drugs and medical devices, the Food and Drug Administration is going to start mining millions of medical records. Not yours, but maybe the ones your hospital has. Nancy Marshall Genzer reports.
Florida just signed a law requiring insurance companies to offer cheap plans without all the extras. But Dan Grech reports the sometimes bare-boned policies can mean you get what you pay for.
For the first time, cancer doctors and researchers have put the abstracts of their cancer studies online in advance of their major annual meeting later this month. And you can bet Wall Street has been poring over the reports. Janet Babin has the story.
Cancer has replaced heart disease as the number one killer of people in their 40's and 50's, and this means growth in oncology drug sales. Janet Babin reports that by 2012, the cancer drug market is set to grow to $80 billion.
